Compare ROIV & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROIV | WST |
|---|---|---|
| Founded | 2014 | 1923 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0B | 18.5B |
| IPO Year | 2021 | 2004 |
| Metric | ROIV | WST |
|---|---|---|
| Price | $30.28 | $327.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $28.94 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 5.9M | 586.8K |
| Earning Date | 05-28-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 1.92 |
| Revenue | $8,260,000.00 | ★ $2,886,900,000.00 |
| Revenue This Year | N/A | $6.76 |
| Revenue Next Year | $744.61 | $6.22 |
| P/E Ratio | ★ N/A | $172.34 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $10.71 | $206.80 |
| 52 Week High | $32.79 | $336.82 |
| Indicator | ROIV | WST |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 61.73 |
| Support Level | $27.44 | $253.53 |
| Resistance Level | $32.79 | N/A |
| Average True Range (ATR) | 0.87 | 8.03 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 86.99 | 67.72 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.